Theranostics earmarked as “the future” of radiopharmaceuticals
As RLTs and theranostics gain prevalence, companies must consider how to overcome their associated regulatory, manufacturing and reimbursement hurdles.
Therapy Area
Significant opportunities exist in the global pain market for novel mechanisms and modalities
Novo sues Hims & Hers despite Wegovy pill offering U-turn
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
GSK’s oncology and HIV drugs drive 7% sales rise in 2025
Corxel raises $287m as obesity continues to spark investor interest
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
J&J’s Caplyta doubles remission rate in MDD patients
